Andrew Grigg

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Kate Manos, Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, Melinda Burgess, Niles Elizabeth Nelson, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, Chun Yew Fong, Eliza A Hawkes

Journal article  |  2023  |  LEUKEMIA

Immune evasion, due to abnormal expression of programmed-death ligands 1 and 2 (PD-L1/PD-L2), predicts poor outcomes with chemoimm..

Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas.

Sun Loo, Andrew Lim, Sze Ting Lee, Andrew Grigg

Journal article  |  2023  |  Clin Lymphoma Myeloma Leuk

BACKGROUND: In patients with relapsed/refractory lymphoma after first line therapy, chemosensitivity to salvage chemotherapy is th..

Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft.

Julia McClelland, Eric Wong, Andrew Grigg

Journal article  |  2023  |  Leuk Lymphoma

Cyclosporine is an immunosuppressive agent to prevent acute graft versus host disease (GVHD) in patients undergoing a stem cell al..

Disseminated Invasive Mucormycosis Infection Following Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Edward R Scheffer Cliff, Gemma Reynolds, Andrew Grigg

Journal article  |  2023  |  Clin Hematol Int

Invasive fungal infections (IFI) are challenging to predict, diagnose and treat, and are associated with a particularly high morta..

Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index.

Tamasine Stewart, Mark Dowling, Brett Janson, Jim Siderov, Jing Xie, Andrew Grigg, Amit Khot

Journal article  |  2023  |  Leuk Lymphoma

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.

Christa Ellen Nath, Andrew Grigg, Sebastian PA Rosser, Jane Estell, Elizabeth Newman, Campbell Tiley, Sundra Ramanathan, Shir Jing Ho, Stephen Larsen, John Gibson, Peter Presgrave, Peter John Shaw, Judith Trotman

Journal article  |  2022  |  Eur J Clin Pharmacol

AIM: To evaluate the accuracy of melphalan test dose pharmacokinetic (PK) predictions of the subsequent high dose (HDM) area under..

Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML

David T Yeung, Naranie Shanmuganathan, John Reynolds, Susan Branford, Mannu Walia, Agnes SM Yong, Jake Shortt, Kate Burbury, Nicholas Viiala, Ilona Cunningham, David M Ross, Rosemary Harrup, Matthew Wright, Cecily Forsyth, Alwyn Bernard D'Souza, Robin J Filshie, Peter J Browett, Steven W Lane, Carolyn Grove, Andrew Grigg, et al.

Journal article  |  2022  |  Blood

Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia

Lynette CY Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, David T Yeung, Timothy Hughes, Naranie Shanmuganathan

Journal article  |  2022  |  Blood

The timing of clinically significant cmv infection following allogeneic haematopoietic cell transplantation (allohct) is associated with poor survival; a national multi-centre cohort study

M Yong, J Lindsay, M Greenwood, SY Tio, J Gallagher, S Ho, MJ Nasra, A Rofe, J Trubiano, A Grigg, J Othman, K Crassini, S Larsen, S vanHal, S Lam, P Boan, D Purtill, T Spelman, A Rivalland, J Sasadeusz, et al.

Conference Proceedings  |  2022  |  BONE MARROW TRANSPLANTATION

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

Paul M Barr, Alessandra Tedeschi, William G Wierda, John N Allan, Paolo Ghia, Daniele Vallisa, Ryan Jacobs, Susan O'Brien, Andrew P Grigg, Patricia Walker, Cathy Zhou, Joi Ninomoto, Gabriel Krigsfeld, Constantine S Tam

Journal article  |  2022  |  CLINICAL CANCER RESEARCH

PURPOSE: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leu..